Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

Background: In first-line treatment of metastatic breast cancer, the best use of the available therapeutic agents is unclear. This study evaluated the efficacy and safety of combined therapy with bevacizumab and gemcitabine.

Patients: Women who were to undergo first-line treatment for locoregionally recurrent or metastatic breast cancer were eligible.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Purpose: The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2)-overexpressing cancer cells. Based on results from a phase I study that showed T-DM1 was well tolerated at the maximum-tolerated dose of 3.6 mg/kg every 3 weeks, with evidence of efficacy, in patients with HER2-positive metastatic breast cancer (MBC) who were previously treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy of T-DM1 in this patient population.

Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.

Hereditary factor VII deficiency is a rare autosomal recessive condition, usually associated with normal or reduced levels of a functionally defective molecule. The available means of treating this condition in North America presents serious health risks to the patient. Transfusion with fresh frozen plasma carries a risk of volume overload and a significant risk for viral transmission.

Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography.

Objective: The purpose of this study was to determine if duplex sonography of the hepatic vasculature can be used to detect venoocclusive disease in patients who have had bone marrow transplantation.

Subjects And Methods: Twenty-seven bone marrow transplant recipients were serially studied with hepatic duplex sonography before (n = 27) and biweekly after (n = 136) transplantation. Duplex waveforms were obtained from the hepatic artery and the portal and hepatic venous systems.

Acute and chronic leukemias in adults.

The progression in understanding the biology of leukemia represents a remarkable bridging of clinical and laboratory science, which has provided much critical knowledge necessary for the design of curative protocols. Drs. Rachel Borson and Virgil Loeb, Jr.

Retained Hickman catheter cuff as an infection source following allogeneic bone marrow transplant.

The case is presented of an infected, retained Hickman catheter cuff in a patient suffering from chronic graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation. This infection seeded to a distant site causing systemic symptoms and requiring inpatient surgical and medical treatment. Although many physicians leave the dacron Hickman cuff in place when removing catheters, the presence of chronic skin changes associated with GVHD may predispose these patients to long-term infectious complications from this retained foreign body.

Regulation of the gene for CD34, a human hematopoietic stem cell antigen, in KG-1 cells.

CD34 is one of the best characterized human hematopoietic stem cell antigens defined to date. It is expressed on 1% to 4% of normal bone marrow cells, including colony forming units of all lineages and their precursors. CD34 expression is lost during hematopoietic development and is not found on mature peripheral blood cells.

Chromosome 1 localization of the gene for CD34, a surface antigen of human stem cells.

CD34 is a surface antigen expressed on normal human hematopoietic stem cells, as well as on the blast cells of many patients with both lymphocytic and myelocytic leukemias. By Southern blot analysis of DNA from a panel of human x mouse somatic cell hybrids using a CD34 cDNA probe, we demonstrate that the gene for CD34 is located on human chromosome 1 in the 1q12----qter region.